cancer sequencing
Although the firm did not provide preliminary financial results for 2024, CEO Chris Smith reaffirmed previous guidance of revenues between $655 million and $667 million.
Cancer Study Sees Tailored Treatment, Outcome Boost with Comprehensive Genomic Profiling
Investigators tracked clinical and treatment outcomes for advanced cancer patients who had tumor testing with an in-house assay developed by Providence Health.
Investigators delved into the prevalence, genetic impacts, inheritance, and potential vulnerabilities of extrachromosomal DNA circles found in a subset of tumors.
Lung Cancer Study Suggests Concurrent RNA, DNA Testing Picks up Actionable SVs
RNA sequencing unearthed actionable structural variants missed with DNA-only sequencing based on tumor assays on 5,570 advanced non-small cell lung cancer cases.
TGen, Soteria Precision Medicine Foundation Partner on Cancer Testing for Soldiers
The partnership will begin by having TGen offer sequencing-based testing, data analysis, and interpretation for patients with solid tumors from the US military’s special operations forces.